Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Neurofibromatosis 2 × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Lung Neoplasms 8 Recurrence 6 Prostatic Neoplasms 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Hepatocellular 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Head and Neck Neoplasms 4 Colorectal Neoplasms 4 Ovarian Neoplasms 3 Myelodysplastic Syndromes 3 Melanoma 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 3 Liver Neoplasms 3 Hematologic Neoplasms 3 Fatigue 3 Esophageal Neoplasms 3 Depression 3 Carcinoma, Squamous Cell 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Parasomnias 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡